Diagnosis and therapy of celiac disease: today and tomorrow

Česká verzia

Authors: M. Bátovský
Authors place of work: Gastroenterologická klinika SZU a UNB, UN sv. Cyrila a Metoda, Bratislava
Published in the journal: Gastroent Hepatol 2012; 66(5): 372-376
Category: Clinical and Experimental Gastroenterology: Review Article

Summary

Increased knowledge of non-invasive markers of celiac disease activity will hopefully enable better initial diagnosis and monitoring of intestinal damage (serological markers, galectin-10, cytokines). Additional celiac disease activity markers are being identified and new targets for treatment are being considered (P31–43 peptide, zonulin). Several new therapeutic approaches for celiac disease are currently under development by targeting its underlying pathogenesis. Alternative therapies range from reproduction of harmless wheat strains to immunomodulatory approaches. Some of these therapies, such as enzymatic cleavage of gluten and permeability inhibitors, have shown promise in clinical studies. Currently, adherence to a gluten-free diet is considered as the first line and indeed only therapy for celiac disease which has been proven to relieve symptoms in most cases and effectively prevent potential complications.

Key words:
celiac disease – gluten enteropathy – gluten-free diet – malabsorption syndrome

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
4. 6. 2012

Accepted:
17. 7. 2012

Zdroje

1. Rashtak S, Murray JA. Coeliac disease, new approaches to therapy. Aliment Pharmacol Ther 2012; 35(7): 768–781.

2. AGA institute medical position statement on the diagnosis and management of celiac disease. Gastroenterology 2006; 131(6): 1977–1980.

3. Armstrong MJ, Hegade VS, Robbins G. Advances in celiac disease. Curr Opin Gastroenterol 2012; 28(2): 104–112.

4. Moore JK, West SRA, Robbins G. Advances in celiac disease. Curr Opin Gastroenterol 2011; 27(2): 112–118.

5. Vivas S, de Morales J. Duodenal biopsy may be avoided when high transglutaminase antibody titers are present. World J Gastroenterol 2009; 15(38): 4775–4780.

6. Zandonadi RP, Botelho RB, Araujo WM. Psyllium as a substitute for gluten in bread. J Am Diet Assoc 2009; 109(10): 1781–1784.

7. Watts RE, Siegel M, Khosla C. Structure-acitivity relationship analysis of the selective inhibition of transglutaminase 2 by dihidroisoxazoles. J Med Chem 2006; 49(25): 7493–7501.

8. Tripathi A, Lammers KM, Goldblum S. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. PNAS 2009; 106(39): 16799–16804.

9. Keech CL, Dromey J, Chen ZJ. Immune tolerance induced by peptide immunotherapy in an HLA DQ2 dependent mouse model of gluten imunity. Gastroenterology 2009; 136: A57.

10. Constantino G, de la Torre A, Lo Presti MA. Treatment of lifethreatening type I refractory coeliac disease with long term infliximab. Dig Liver Dis 2008; 40(1): 74–77.

11. Malamut G, El Machhour R, Montcuquet N. IL-15 trigger an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease associated inflammation and lymphomagenesis. J Clin Invest 2010; 120(6): 2131–2143.